Ms. Yang Ling 杨凌
- 凯雷投资集团董事总经理
Ling Yang is a Managing Director at The Carlyle Group. She is co-head of Carlyle Asia Healthcare and is primarily responsible for Carlyle’s healthcare investment and portfolio activities in China. Ms. Yang began her career at Carlyle focusing on healthcare for the U.S. Buyout group and joined Carlyle Asia in 2011. Since joining Carlyle Asia, Ms. Yang has led investments into leading healthcare companies in China including Hutchmed, Adicon Clinical Laboratories, Ambiopharm, Microport Scientific Corporation, Meinian Onehealth, and Shenzhen Salubris Pharmaceuticals. She chairs the board of Adicon Clinical Laboratories and is a member of the boards of Ambiopharm and Shenzhen Salubris.
杨凌女士现任职于凯雷投资集团，担任董事总经理职位，是凯雷亚洲医疗健康业务的联席主管，主要负责凯雷在大中华区医疗行业的投资业务。杨女士在凯雷投资集团美国并购组开始职业生涯，专注于医疗行业，并于2011年加入凯雷亚洲。自加入凯雷亚洲以来，杨凌女士已领导了多个对中国一些最具活力的医疗投资项目，其中包括和黄医药、艾迪康医学检验中心、昂博生物、微创医疗科学，美年大健康和深圳信立泰药业。她目前担任艾迪康医学检验中心的董事长，以及深圳信立泰药业与昂博生物的董事会成员。